TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.17), in-line with the analyst estimate of ($0.17). Revenue for the quarter came in at $5.09 million versus the consensus estimate of $5 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.